Merck & Co., Inc. vs Pfizer Inc.: Strategic Comparison

This in-depth comparison examines Merck & Co., Inc. and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Merck & Co., Inc. on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Merck & Co., Inc. and Pfizer Inc. is widest.

On the headline numbers, Merck & Co., Inc. reports annual revenue of $65.0B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $215.0B and $148.0B. Merck & Co., Inc. is headquartered in United States and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.

Merck & Co., Inc.: Keytruda generated approximately $29.5 billion in fiscal year 2024 — the highest annual revenue of any pharmaceutical product in history. A single drug. From a company with $63.6 billion in total net sales, that one molecule accounts for 46% of the entire revenue base. The concentration is extraordinary. It is also the result of one of the most consequential licensing decisions in pharmaceutical history: Merck acquired the rights to pembrolizumab from Organon in 2009 for a payment that, in retrospect, was profoundly underpriced. Merck and Co. Inc. Employs approximately 74,000 people across more than 140 countries. Headquartered in Rahway, New Jersey, the company develops and markets prescription medicines, vaccines, biologic therapies, and animal health products. Maurice Hilleman, a Merck scientist who worked at the company from 1957 until his death in 2005, developed more human vaccines than any other scientist in history — an estimated 40 vaccines including measles, mumps, rubella, hepatitis A, hepatitis B, and chickenpox. That scientific legacy shaped the institutional culture that eventually recognized pembrolizumab's potential when others were focused on rival compounds. CEO Robert M. Davis leads a company facing the most discussed patent cliff in pharmaceuticals: Keytruda's US market exclusivity expires around 2028. What happens after 2028 depends on how successfully Merck has diversified its pipeline and how aggressively biosimilar manufacturers enter the pembrolizumab market. The company's active Keytruda clinical trial program encompasses more than 1,600 studies involving more than 300,000 patients globally — the most extensive single-drug clinical program ever conducted, designed in part to extend the drug's utility across new indications before the patent expires. The American independence of Merck is itself a consequence of war: the US government seized the German-owned American subsidiary in 1917 under the Trading with the Enemy Act, and the American management team purchased it. The German entity — E. Merck of Darmstadt — continues to operate independently today under the same name.

Pfizer Inc.: Pfizer supplied 90% of the penicillin used by Allied forces at D-Day — decades before it became a household brand. That 1944 wartime logistics operation was not a detour from the pharmaceutical business; it was the moment the pharmaceutical business became possible at Pfizer. The fermentation expertise developed for penicillin production became the foundation for every drug manufacturing operation that followed. One hundred seventy-five years after Charles Pfizer and Charles Erhart launched a small chemical operation in Brooklyn, the company they started generates $63.6 billion in annual revenue and employs 88,000 people across more than 125 countries. The founding capital was $2,500 — equivalent to roughly $90,000 in 2024 dollars. The market capitalization is $148 billion. That arithmetic describes a compounding machine built on a specific capability: finding molecules that modify human biology in precise, repeatable, profitable ways. The COVID-19 vaccine partnership with BioNTech produced revenues of $100.3 billion in fiscal year 2022 — a figure so anomalous it requires a second reading. Pfizer's pre-pandemic revenue was roughly $42 billion. The vaccine added $58 billion in a single year. The subsequent normalization to $63.6 billion in 2024 looks like a decline against 2022's peak but represents a genuine improvement over the pre-pandemic baseline. Understanding Pfizer without this context produces a distorted picture. Albert Bourla has led the company since 2019 through the most financially consequential period in its history. The Oncology portfolio — Ibrance, Xtandi, Eliquis — generates billions in recurring revenue. The Seagen acquisition completed in 2023 added antibody-drug conjugate technology that management has described as the foundation for the next decade of oncology growth.

Merck & Co., Inc. and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Merck & Co., Inc. and Pfizer Inc..

Merck & Co., Inc. business model: When Merck & Co. Licensed pembrolizumab — the compound that would eventually become Keytruda — from Organon in 2009 for a modest upfront payment, the PD-1 pathway it targeted was considered a promising but scientifically crowded corner of immuno-oncology where Bristol Myers Squibb appeared to hold a decisive lead. The pricing power underlying Keytruda's revenue is substantial and structurally embedded. The competitive risk in vaccines is not from scientific rivals but from public health and pricing dynamics: government procurement decisions in large markets like China can shift billions of dollars of revenue with little commercial warning, as the 2023-2024 China pullback demonstrated. Pricing pressure in the United States escalated in a structurally new way with the implementation of Medicare drug price negotiation provisions under the Inflation Reduction Act of 2022. That antibody, identified through research conducted at Schering-Plough's Organon BioSciences subsidiary and subsequently licensed to Merck, would be developed through a decade of clinical investment into pembrolizumab — the compound that became Keytruda.

Pfizer Inc. business model: Pfizer's ability to set premium pricing in the United States — where pharmaceutical pricing is largely unregulated compared to European reference pricing systems — is therefore central to overall profitability. The Inflation Reduction Act of 2022, which for the first time authorizes Medicare to negotiate drug prices directly with manufacturers, represents a structural change to this pricing model that Pfizer and its peers are still quantifying in terms of long-term revenue impact. The Inflation Reduction Act's Medicare drug price negotiation provisions directly threaten pricing power on several Pfizer products, including Eliquis, which was among the first ten drugs selected for negotiation. Internationally, reference pricing systems in Europe and government procurement leverage in emerging markets continue to compress net realized prices on Pfizer's portfolio. Public scrutiny of pharmaceutical pricing practices — which intensified during the COVID-19 pandemic when Pfizer's commercial success from government-funded vaccine development became a political flashpoint — has sustained pressure on the company's pricing and communications strategy. By formulating santonin with almond toffee to mask its bitter taste, Pfizer created one of the early examples of what we would today call a value-added pharmaceutical formulation — the active ingredient combined with delivery mechanisms designed to improve patient compliance.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Merck & Co., Inc. stack up against those of Pfizer Inc..

Merck & Co., Inc. competitive advantage: In non-small cell lung cancer — the prize indication given its prevalence and commercial scale — Merck pursued and won first-line approval with a companion diagnostic selecting patients with high PD-L1 expression, a strategy that created a diagnostically defined patient population where Keytruda's efficacy data were particularly compelling. The clinical trial network Merck has constructed around Keytruda is arguably the most significant competitive moat in the pharmaceutical industry today and one that will endure well beyond the patent expiration date. In animal health, Merck's competitive advantage rests on two mutually reinforcing foundations: the breadth and scientific depth of its vaccine portfolio in livestock — where preventing infectious disease is economically far more valuable than treating it — and the rapidly growing companion animal portfolio anchored by Bravecto's parasite prevention leadership and Librela's novel mechanism in canine pain management. This application of human pharmaceutical research capabilities to veterinary medicine creates a durable innovation advantage that is structural rather than dependent on any specific product's commercial performance. Merck's scientific reputation — built over 130 years and anchored by innovations from the first commercially available statin to the hepatitis B vaccine to the cancer immunotherapy revolution — also provides a less quantifiable but genuinely meaningful competitive advantage in recruiting research talent and forming academic and government partnerships. The ability to attract oncologists, immunologists, and drug developers who want their work to reach the highest-impact platform available is a compounding talent advantage that reinforces the clinical trial execution quality and scientific credibility that commercial success requires. An IBD drug of that scale would establish a second major disease area franchise alongside oncology and would meaningfully diversify Merck's revenue away from its current near-total dependence on Keytruda.

Pfizer Inc. competitive advantage: The scale was almost incomprehensible: at its 2022 peak, Pfizer was earning more revenue from two COVID products than Apple earned from the entire iPhone franchise. Its pivotal moment came during World War II, when the U.S. Government urgently needed a domestic producer capable of manufacturing penicillin at industrial scale. This integrated manufacturing capability — rare among companies of Pfizer's scale in an era of widespread outsourcing to contract manufacturers — provided decisive operational advantage during the COVID-19 vaccine rollout, when Pfizer manufactured and delivered more than 4 billion doses of Comirnaty globally within 24 months of the vaccine's development. Its R&D operations span Cambridge, Massachusetts; La Jolla, California; Groton, Connecticut; and Pearl River, New York — a geographic distribution that mirrors the broader American pharmaceutical research ecosystem and ensures access to the academic and biotech talent clusters that have become increasingly important as the industry's innovation model has shifted toward external licensing and collaboration. Pfizer today occupies a strategic position that is simultaneously enviable — vast scale, global brand recognition, proven manufacturing capability — and precarious, as its product portfolio navigates one of the most challenging patent transition periods in its history. The debt load represents the most significant financial constraint on Pfizer's near-term strategic flexibility, limiting the scale of additional acquisitions without asset disposals or credit rating deterioration. The first and perhaps most foundational is manufacturing scale and global supply chain integration. Pfizer operates one of the largest biopharmaceutical manufacturing networks in the world, with facilities capable of producing small molecules, biologics, sterile injectables, and, following the COVID experience, mRNA-based vaccines at industrial scale. The second structural advantage is Pfizer's clinical development and regulatory expertise — what the industry calls its regulatory affairs capability. This creates what economists call a 'first mover cost advantage' for Pfizer in markets where it already has a sales footprint.

Future prospects matter as much as current results. The growth strategies below explain how Merck & Co., Inc. and Pfizer Inc. each plan to expand from here.

Merck & Co., Inc. growth strategy: Inside Merck's research organization, there were serious discussions in 2011 about whether to continue investing in the program at all. The decision to press forward, accelerate development, and pursue a bold regulatory strategy of seeking approval in melanoma before completing standard Phase 3 trials is arguably the most consequential single R&D decision in modern pharmaceutical history. That extraordinary commercial success has made Merck & Co. Simultaneously one of the most admired companies in the pharmaceutical industry and one of the most closely watched by investors tracking a specific date: 2028, when Keytruda's core U.S. Patent protection is scheduled to expire. Under CEO Robert M. Davis, the company is executing an aggressive business development strategy centered on building pipeline assets capable of replacing Keytruda revenue after its primary U.S. Patent expires in 2028, deploying approximately $50 billion in acquisitions and partnerships since 2021. Key near-term growth drivers include Winrevair for pulmonary arterial hypertension, tulisokibart for inflammatory bowel disease, and subcutaneous Keytruda, which could meaningfully extend the franchise's commercial life. The companion animal business — led by the Bravecto flea and tick prevention product and the Librela canine pain management monoclonal antibody — is the higher-margin and faster-growing component, benefiting structurally from the pet humanization trend that has increased per-pet veterinary spending substantially in developed markets. Merck's manufacturing and supply chain infrastructure represents a substantial competitive asset that is often overlooked in financial analysis focused on R&D pipelines. Biologic manufacturing is one of the least visible but most durable elements of Merck's competitive moat, and its capacity investments — which have expanded significantly since 2018 to support Keytruda's global rollout — will also accommodate the next generation of biologic products as the pipeline matures toward approval. The divergence in their subsequent commercial trajectories illustrates how decisive early clinical and regulatory strategy can be in pharmaceutical competition. Merck pursued an aggressive single-agent approval in melanoma using a breakthrough therapy designation and accelerated approval pathway, generating physician experience and clinical credibility before Opdivo in that indication. Opdivo's Phase 3 trial in first-line lung cancer, by contrast, was designed without a PD-L1 selection strategy and failed — a pivotal clinical misstep that ceded first-line lung cancer market leadership to Keytruda at the moment the market was being established. The drug's novel mechanism — targeting activin signaling to rebalance the growth-apoptosis equilibrium in pulmonary arterial smooth muscle cells — addresses a pathway no prior PAH drug has touched, making it scientifically additive rather than merely competitive with existing therapies. Across all competitive arenas, the pattern that recurs in Merck's history is that clinical development strategy — where to run a trial, which patient population to define, which endpoint to power, which regulatory pathway to pursue — is as commercially decisive as scientific innovation. Merck & Co.'s fiscal year 2024 financial results reflected the extraordinary commercial power of the Keytruda franchise operating at peak — and the building investment pressure required to construct a pipeline capable of sustaining that revenue base after 2028. Geographic concentration risk intensified in 2023 and 2024 as China — which had been the largest international growth market for Gardasil — abruptly reduced procurement volumes following domestic policy decisions and apparent diplomatic considerations. Merck's growth strategy under CEO Robert M. Davis is organized around four interconnected priorities: maximizing Keytruda's remaining patent-protected commercial window, commercially executing Winrevair's global launch, advancing the business development-sourced pipeline toward regulatory approval, and building new disease area franchises through both internal research and external partnership. On Keytruda maximization, the strategy involves pursuing additional indications — particularly in earlier-stage cancers where the drug is being evaluated as adjuvant therapy following surgery, theoretically expanding the eligible patient population far beyond the metastatic patients who represent its current core — while simultaneously advancing subcutaneous formulation to protect the franchise post-2028. The adjuvant strategy is particularly significant: Keytruda is already approved as adjuvant therapy in melanoma, renal cell carcinoma, and non-small cell lung cancer, and its ongoing trials in earlier-stage colon cancer, bladder cancer, and gastric cancer could substantially broaden the treated population and extend the revenue life of the franchise independent of biosimilar dynamics. Antibody-drug conjugates, which combine the targeting precision of monoclonal antibodies with the cell-killing potency of cytotoxic chemotherapy payloads, represent the fastest-growing class in oncology and the natural complement to Keytruda in combination treatment strategies. The Daiichi Sankyo partnership effectively buys Merck a meaningful position in next-generation oncology without requiring it to build an internal ADC manufacturing and chemistry capability from scratch. Merck has also explicitly flagged cardiometabolic disease and infectious disease as growth areas where business development is actively targeted. Together, these business development priorities represent a deliberate effort to build a portfolio broad enough that the post-2028 revenue trajectory does not depend on any single pipeline success. Beyond these three near-term catalysts, management has identified a portfolio of earlier-stage assets across oncology, cardiometabolic disease, and infectious disease that represents the next layer of the post-2028 revenue bridge — a portfolio intentionally built with sufficient breadth that no single clinical failure is capable of invalidating the entire succession strategy. The American subsidiary grew steadily through the 1890s and 1900s, importing German-manufactured pharmaceuticals for the U.S. Market and gradually building domestic manufacturing capacity. The profits follow, and if we have remembered that, they have never failed to appear.' This philosophy — whether sincere conviction or canny public relations, it was almost certainly both — shaped a research investment culture that produced an extraordinary string of medical discoveries in the mid-twentieth century.

Pfizer Inc. growth strategy: The Seagen deal represented Pfizer's most explicit bet yet that oncology, not infectious disease, would define its next chapter of growth. For American investors, patients, policymakers, and anyone interested in how large corporations navigate the intersection of science, capital, and public health expectations, Pfizer's trajectory offers a uniquely instructive case study. Whether it can engineer another sustained growth cycle through oncology innovation, rare disease expansion, and next-generation vaccines remains the defining question of its current strategic era. Understanding how Pfizer actually makes money requires examining four distinct but interconnected revenue mechanisms: branded small molecule drugs, biologics and large-molecule therapies, vaccines, and the emerging antibody-drug conjugate oncology platform it acquired through Seagen. Oncology has become Pfizer's most strategically important growth segment following the Seagen acquisition. This modality represents one of the fastest-growing technology platforms in oncology, and Pfizer's Seagen acquisition positioned it alongside AstraZeneca-Daiichi Sankyo as the dominant force in the space. The rapid decline of Paxlovid revenues illustrates the fundamental volatility embedded in pandemic-related revenue streams and the critical importance of Pfizer's diversification strategy beyond COVID products. The company's R&D productivity — measured by the ratio of successful drug approvals to total development spending — has historically been below industry benchmarks, a chronic challenge that has driven repeated restructuring of research operations and therapeutic focus areas. The manufacturing network also creates substantial fixed cost structure that requires sustained revenue throughput to remain efficient, which partially explains why Pfizer has historically preferred large acquisitions over organic R&D alone as a growth mechanism. While Pfizer has been managing post-COVID revenue normalization and absorbing the Seagen acquisition, Eli Lilly has experienced a historically unusual pharmaceutical growth trajectory driven by tirzepatide (Mounjaro/Zepbound) and dulaglutide in the GLP-1 receptor agonist therapeutic area. The contrast is instructive: both companies are large-cap pharmaceutical manufacturers with substantial R&D investment, but their portfolio mix and pipeline timing have produced dramatically different investor outcomes in the early 2020s. The company's danuglipron oral GLP-1 program was discontinued in late 2023 due to adverse event profile concerns, a setback that eliminated what might have been a significant late-stage pipeline asset in the highest-growth category in medicine. Its Vyndaqel/Vyndamax franchise for transthyretin amyloid cardiomyopathy (ATTR-CM) has faced growing competition from Alnylam Pharmaceuticals' Onpattro and Amvuttra, which use RNA interference technology to reduce TTR protein production rather than stabilizing misfolded TTR as Pfizer's approach does. Through its Upjohn division spin-off in 2020 — which merged with Mylan to form Viatris — Pfizer exited the off-patent generics business, sharpening its competitive focus on patented branded pharmaceuticals and biologics. In aggregate, Pfizer's management has acknowledged that products representing approximately $17-18 billion in annual revenues face loss of exclusivity between 2025 and 2030, creating a revenue gap that the company's internal pipeline and acquired assets must collectively bridge. Pfizer paid a substantial premium for Seagen, implying aggressive growth expectations for the ADC platform that will require successful late-stage clinical trial readouts and commercial execution to justify. The company has successfully navigated FDA and EMA approval processes for hundreds of drug products over more than seven decades, building institutional knowledge about study design, data presentation, and regulatory negotiation that meaningfully increases the probability of successful approval for late-stage pipeline compounds. Third, Pfizer's global commercial infrastructure — its network of sales forces, medical affairs teams, market access specialists, and distribution relationships across more than 125 countries — creates a deployment platform for new products that smaller companies must either build from scratch or access through partnership. Pfizer's growth strategy for the period 2025-2030 rests on four interconnected pillars designed to rebuild revenue momentum following the post-pandemic contraction. The first and most immediate pillar is maximizing value from the Seagen oncology portfolio through label expansions, combination therapy approvals, and geographic market launches in Japan, China, and emerging market territories where Seagen's commercial footprint was limited prior to the acquisition. Pfizer's commercial infrastructure in these markets — already established through its branded pharmaceutical and vaccine businesses — provides the distribution platform to accelerate Seagen product uptake without the overhead of building new commercial organizations. Pfizer's gene therapy ambitions, built on the 2016 acquisition of Bamboo Therapeutics and subsequent platform development, represent a potentially transformational but still scientifically uncertain long-term growth avenue. The $4 billion cost reduction program announced in 2023 and the subsequent $1.5 billion additional savings initiative are designed to maintain competitive margins while revenue recovers, creating financial capacity for continued R&D investment without proportional overhead growth. The fourth pillar is maintaining and growing the dividend, which at approximately $1.68 per share annually remains a critical component of the investment thesis for Pfizer's large retail and institutional income-oriented shareholder base. The dividend's sustainability depends on free cash flow generation consistently exceeding capital requirements — a bar that Pfizer's management is under sustained investor scrutiny to clear. Clinical trial data from ongoing Phase 3 studies in multiple tumor types through 2025-2027 will be pivotal in determining whether the Seagen investment creates the expected value. In 1849, with $2,500 borrowed from Pfizer's father — a sum equivalent to roughly $90,000 in 2024 dollars — the two cousins established Charles Pfizer and Company in a red brick building on Bartlett Street in Brooklyn. The santonin business was modestly successful, but Pfizer's decisive early growth came from an entirely different product category: citric acid. Pfizer's fermentation technology — derived from the same biological science used in drug compound production — allowed domestic production at scale for the first time, rapidly expanding revenues and establishing manufacturing processes that would prove strategically critical a century later.

A closer look at the financial trajectory of Merck & Co., Inc. and Pfizer Inc. rounds out the comparison.

Merck & Co., Inc.: Revenue ran at $48.7 billion in FY2021, $59.3 billion in FY2022, $58.5 billion in FY2023, and $65B in FY2025. The FY2024 increase was driven by Keytruda volume growth across expanding indications. Net income of $15.62 billion in FY2024 implied a 24.6% net margin — high for a company that invests approximately $16.4 billion annually in R&D, representing roughly 26% of net sales. Merck's R&D intensity — 26% of net sales dedicated to research — is one of the highest among large-cap pharmaceutical companies globally. The approximately $16.4 billion invested in FY2024 funds Keytruda's more than 1,600 active clinical studies, pipeline assets in cardiovascular disease, oncology, vaccines, and infectious disease, and the early-stage discovery programs that will define the company's revenue base after 2028. Market capitalization of $215 billion against $63.6 billion in revenue reflects both the current profitability and the market's assessment of the Keytruda cliff risk. Biosimilar pembrolizumab will eventually enter the market after the US exclusivity expires around 2028, and the revenue erosion curve for biosimilar biologics is genuinely uncertain — slower than small molecule generics, but real. Every acquisition Merck has made in recent years is partly an attempt to pre-fund the post-Keytruda revenue base. The Vioxx withdrawal in 2004 and the resulting $4.85 billion liability settlement remains the most financially damaging product safety event in the company's history. The Inflation Reduction Act legal challenge over Januvia pricing and the Gardasil China pullback in 2023 represent newer regulatory and market access risks that run in parallel with the Keytruda cliff as material financial considerations.

Pfizer Inc.: Pfizer's revenue in 2021 was $81.3 billion. In 2022 it was $100.3 billion — the COVID vaccine and Paxlovid antiviral together added roughly $57 billion in revenue in their peak year. In 2023, as vaccine demand normalized and governments stopped stockpiling antivirals, revenue fell to $58.5 billion. By FY2025 it had recovered to $62.6B. These four data points describe a company whose underlying business is growing, distorted by an extraordinary windfall and its subsequent normalization. Net income of $8.0 billion in 2024 sits against a market capitalization of $148 billion — a price-to-earnings ratio that reflects both the earnings recovery from the 2023 decline and investor uncertainty about the patent cliff ahead. Key drugs in the portfolio face generic competition over the next five to seven years, a structural challenge that every large pharmaceutical company manages through pipeline investment and acquisitions. The $43 billion Seagen acquisition completed in 2023 was the largest deployment of COVID-era capital. Seagen's antibody-drug conjugate technology — engineered molecules that deliver chemotherapy directly to cancer cells — represents a platform Pfizer management believes will generate multiple blockbuster drugs. The financial case requires those drugs to actually reach market and achieve commercial adoption, a process measured in years. Pfizer's founding investment of $2,500 in 1849 grew into the company that produced the first major mRNA vaccine at commercial scale in 2021. The $90,000 equivalent starting capital and the $148 billion current market cap represent 175 years of compounding through exactly the reinvestment-in-discovery cycle that has characterized every major pharmaceutical innovator. The question is whether that cycle continues to generate the next Lipitor, the next Paxlovid — or whether the patent expirations ahead will require the next defining acquisition to maintain the revenue trajectory.